
Claims

1. A compound of formula I



I

wherein,

A is –O– or CH_2;

R^1 is hydroxyalkyl or acetyl;

R^2 is alkyl;

n is 0 or 1;

wherein if n is 0 then A is CH_2.

and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, wherein R^1 is hydroxyalkyl.

3. A compound according to claim 1 to 2, wherein R^2 is methyl.

4. A compound according to any one of claims 1 to 3, selected from

3-(4-Hydroxy-2,3-dihydrobenzofuran-5-yl)-6-[[(3*R*)-1-(2-hydroxyethyl)-3-piperidyl]amino]-4-methyl-1,2,4-triazin-5-one;

6-[[(3*R*)-1-(2-Hydroxyethyl)-3-piperidyl]amino]-3-(4-hydroxyindan-5-yl)-4-methyl-1,2,4-triazin-5-one;

and pharmaceutically acceptable salts thereof.

5. A compound according to any one of claims 1 to 3, selected from

3-(4-hydroxyindan-5-yl)-6-[[(3R)-1-(3-hydroxypropyl)-3-piperidyl]amino]-4-methyl-1,2,4-triazin-5-one;

3-(2-hydroxy-3-bicyclo[4.2.0]octa-1(6),2,4-trienyl)-6-[[(3R)-1-(2-hydroxyethyl)-3-piperidyl]amino]-4-methyl-1,2,4-triazin-5-one;

and pharmaceutically acceptable salts thereof.

6. A compound according to claim 1, wherein the compound is 6-[[(3R)-1-Acetyl-3-piperidyl]amino]-3-(4-hydroxyindan-5-yl)-4-methyl-1,2,4-triazin-5-one, or a pharmaceutically acceptable salts thereof.

7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 and a therapeutically inert carrier.

8. A compound according to any one of claims 1 to 6 for use as a therapeutically active substance.

9. A compound according to any one of claims 1 to 6 for use in the treatment or prevention of a disease, disorder or condition, wherein the disease, disorder or condition is responsive to NLRP3 inhibition.

10. A compound according to any one of claims 1 to 6 for the treatment or prophylaxis of a disease, disorder or condition selected from Asthma or COPD.

11. The use of a compound according to any one of claims 1 to 6 for the treatment or prophylaxis of a disease, disorder or condition, wherein the disease, disorder or condition is responsive to NLRP3 inhibition.

12. The use of a compound according to any one of claims 1 to 6 in the treatment or prophylaxis of a disease, disorder or condition selected from Asthma or COPD.

13. The use of a compound according to any one of claims 1 to 6 for the preparation of a medicament for the treatment or prophylaxis of a disease, disorder or condition selected from Asthma or COPD.

14. A method of inhibiting NLRP3, which method comprises administering an effective amount of a compound as claimed in any one of claims 1 to 6 to inhibit NLRP3.

15. A method for the treatment or prophylaxis of a disease, disorder or condition, which method comprises administering an effective amount of a compound according to any one of claims 1 to 6 wherein the disease, disorder or condition is selected from Asthma or COPD.